| 1. Berardi F, Loiodice F, Fracchiolla G, Colabufo NA, Perrone R, Tortorella V.. (2003) Synthesis of chiral 1-[omega-(4-chlorophenoxy)alkyl]-4-methylpiperidines and their biological evaluation at sigma1, sigma2, and sterol delta8-delta7 isomerase sites., 46 (11): [PMID:12747784] [10.1021/jm021014d] |
| 2. Chenard BL, Shalaby IA, Koe BK, Ronau RT, Butler TW, Prochniak MA, Schmidt AW, Fox CB.. (1991) Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds., 34 (10): [PMID:1681106] [10.1021/jm00114a018] |
| 3. Belliotti TR, Wustrow DJ, Brink WA, Zoski KT, Shih YH, Whetzel SZ, Georgic LM, Corbin AE, Akunne HC, Heffner TG, Pugsley TA, Wise LD.. (1999) A series of 6- and 7-piperazinyl- and -piperidinylmethylbenzoxazinones with dopamine D4 antagonist activity: discovery of a potential atypical antipsychotic agent., 42 (25): [PMID:10602703] [10.1021/jm990277d] |
| 4. Berardi F, Ferorelli S, Abate C, Pedone MP, Colabufo NA, Contino M, Perrone R.. (2005) Methyl substitution on the piperidine ring of N-[omega-(6-methoxynaphthalen-1-yl)alkyl] derivatives as a probe for selective binding and activity at the sigma(1) receptor., 48 (26): [PMID:16366605] [10.1021/jm050654o] |
| 5. Ferorelli S, Abate C, Colabufo NA, Niso M, Inglese C, Berardi F, Perrone R.. (2007) Design and evaluation of naphthol- and carbazole-containing fluorescent sigma ligands as potential probes for receptor binding studies., 50 (19): [PMID:17713896] [10.1021/jm070373b] |
| 6. Alarcon K, Martz A, Mony L, Neyton J, Paoletti P, Goeldner M, Foucaud B.. (2008) Reactive derivatives for affinity labeling in the ifenprodil site of NMDA receptors., 18 (9): [PMID:18434149] [10.1016/j.bmcl.2008.04.019] |
| 7. Tahirovic YA, Geballe M, Gruszecka-Kowalik E, Myers SJ, Lyuboslavsky P, Le P, French A, Irier H, Choi WB, Easterling K, Yuan H, Wilson LJ, Kotloski R, McNamara JO, Dingledine R, Liotta DC, Traynelis SF, Snyder JP.. (2008) Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists., 51 (18): [PMID:18800760] [10.1021/jm8002153] |
| 8. Berardi F, Abate C, Ferorelli S, de Robertis AF, Leopoldo M, Colabufo NA, Niso M, Perrone R.. (2008) Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity., 51 (23): [PMID:19053780] [10.1021/jm800965b] |
| 9. Gitto R, De Luca L, Ferro S, Citraro R, De Sarro G, Costa L, Ciranna L, Chimirri A.. (2009) Development of 3-substituted-1H-indole derivatives as NR2B/NMDA receptor antagonists., 17 (4): [PMID:19157884] [10.1016/j.bmc.2008.12.058] |
| 10. Zampieri D, Mamolo MG, Laurini E, Florio C, Zanette C, Fermeglia M, Posocco P, Paneni MS, Pricl S, Vio L.. (2009) Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives., 52 (17): [PMID:19673530] [10.1021/jm900366z] |
| 11. Berardi F, Abate C, Ferorelli S, Uricchio V, Colabufo NA, Niso M, Perrone R.. (2009) Exploring the importance of piperazine N-atoms for sigma(2) receptor affinity and activity in a series of analogs of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28)., 52 (23): [PMID:19842660] [10.1021/jm9007505] |
| 12. Mony L, Triballeau N, Paoletti P, Acher FC, Bertrand HO.. (2010) Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach., 20 (18): [PMID:20692832] [10.1016/j.bmcl.2010.07.043] |
| 13. Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.. (2007) Chemical genetics reveals a complex functional ground state of neural stem cells., 3 (5): [PMID:17417631] [10.1038/nchembio873] |
| 14. Fuchigami T, Yamaguchi H, Ogawa M, Biao L, Nakayama M, Haratake M, Magata Y.. (2010) Synthesis and biological evaluation of radio-iodinated benzimidazoles as SPECT imaging agents for NR2B subtype of NMDA receptor., 18 (21): [PMID:20875744] [10.1016/j.bmc.2010.08.053] |
| 15. Tewes B, Frehland B, Schepmann D, Schmidtke KU, Winckler T, Wünsch B.. (2010) Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols., 18 (22): [PMID:20965739] [10.1016/j.bmc.2010.09.026] |
| 16. PubChem BioAssay data set, |
| 17. PubChem BioAssay data set, |
| 18. Sinha N, Sen S.. (2011) Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model., 46 (2): [PMID:21185626] [10.1016/j.ejmech.2010.11.042] |
| 19. Labas R, Gilbert G, Nicole O, Dhilly M, Abbas A, Tirel O, Buisson A, Henry J, Barré L, Debruyne D, Sobrio F.. (2011) Synthesis, evaluation and metabolic studies of radiotracers containing a 4-(4-[18F]-fluorobenzyl)piperidin-1-yl moiety for the PET imaging of NR2B NMDA receptors., 46 (6): [PMID:21453995] [10.1016/j.ejmech.2011.03.013] |
| 20. PubChem BioAssay data set, |
| 21. PubChem BioAssay data set, |
| 22. PubChem BioAssay data set, |
| 23. Ferorelli S, Abate C, Pedone MP, Colabufo NA, Contino M, Perrone R, Berardi F.. (2011) Synthesis and binding assays of novel 3,3-dimethylpiperidine derivatives with various lipophilicities as σ₁ receptor ligands., 19 (24): [PMID:22075234] [10.1016/j.bmc.2011.10.023] |
| 24. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
| 25. Simoni E, Daniele S, Bottegoni G, Pizzirani D, Trincavelli ML, Goldoni L, Tarozzo G, Reggiani A, Martini C, Piomelli D, Melchiorre C, Rosini M, Cavalli A.. (2012) Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease., 55 (22): [PMID:23033965] [10.1021/jm3009458] |
| 26. Gitto R, De Luca L, Ferro S, Buemi MR, Russo E, De Sarro G, Chisari M, Ciranna L, Chimirri A.. (2012) Synthesis and biological characterization of 3-substituted 1H-indoles as ligands of GluN2B-containing N-methyl-D-aspartate receptors. Part 2., 55 (23): [PMID:23140383] [10.1021/jm301508d] |
| 27. PubChem BioAssay data set, |
| 28. Trippier PC, Jansen Labby K, Hawker DD, Mataka JJ, Silverman RB.. (2013) Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers., 56 (8): [PMID:23458846] [10.1021/jm3015926] |
| 29. Gitto R, De Luca L, Ferro S, Scala A, Ronsisvalle S, Parenti C, Prezzavento O, Buemi MR, Chimirri A.. (2014) From NMDA receptor antagonists to discovery of selective σ₂ receptor ligands., 22 (1): [PMID:24290063] [10.1016/j.bmc.2013.11.014] |
| 30. Gitto R, De Luca L, Ferro S, Russo E, De Sarro G, Chisari M, Ciranna L, Alvarez-Builla J, Alajarin R, Buemi MR, Chimirri A.. (2014) Synthesis, modelling and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-d-aspartate receptors., 22 (3): [PMID:24411196] [10.1016/j.bmc.2013.12.040] |
| 31. Gawaskar S, Schepmann D, Bonifazi A, Wünsch B.. (2014) Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines., 22 (23): [PMID:25458498] [10.1016/j.bmc.2014.10.004] |
| 32. PubChem BioAssay data set, |
| 33. Buemi MR, De Luca L, Ferro S, Russo E, De Sarro G, Gitto R.. (2016) Structure-guided design of new indoles as negative allosteric modulators (NAMs) of N-methyl-D-aspartate receptor (NMDAR) containing GluN2B subunit., 24 (7): [PMID:26912202] [10.1016/j.bmc.2016.02.021] |
| 34. WHO Anatomical Therapeutic Chemical Classification, |
| 35. British National Formulary (72nd edition), |
| 36. Dey S, Schepmann D, Wünsch B.. (2018) 2-Methyltetrahydro-3-benzazepin-1-ols - The missing link in SAR of GluN2B selective NMDA receptor antagonists., 26 (2): [PMID:29254894] [10.1016/j.bmc.2017.12.010] |
| 37. Dey S, Temme L, Schreiber JA, Schepmann D, Frehland B, Lehmkuhl K, Strutz-Seebohm N, Seebohm G, Wünsch B.. (2017) Deconstruction - reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors., 138 [PMID:28704758] [10.1016/j.ejmech.2017.06.068] |
| 38. Temme L, Frehland B, Schepmann D, Robaa D, Sippl W, Wünsch B.. (2018) Hydroxymethyl bioisosteres of phenolic GluN2B-selective NMDA receptor antagonists: Design, synthesis and pharmacological evaluation., 144 [PMID:29289890] [10.1016/j.ejmech.2017.12.054] |
| 39. Shuto Y, Thum S, Temme L, Schepmann D, Kitamura M, Wünsch B.. (2017) Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?, 8 (5): [PMID:30108812] [10.1039/C6MD00621C] |
| 40. Schreiber JA, Müller SL, Westphälinger SE, Schepmann D, Strutz-Seebohm N, Seebohm G, Wünsch B.. (2018) Systematic variation of the benzoylhydrazine moiety of the GluN2A selective NMDA receptor antagonist TCN-201., 158 [PMID:30218911] [10.1016/j.ejmech.2018.09.006] |
| 41. Rui M, Rossino G, Coniglio S, Monteleone S, Scuteri A, Malacrida A, Rossi D, Catenacci L, Sorrenti M, Paolillo M, Curti D, Venturini L, Schepmann D, Wünsch B, Liedl KR, Cavaletti G, Pace V, Urban E, Collina S.. (2018) Identification of dual Sigma1 receptor modulators/acetylcholinesterase inhibitors with antioxidant and neurotrophic properties, as neuroprotective agents., 158 [PMID:30223122] [10.1016/j.ejmech.2018.09.010] |
| 42. Zscherp R, Baumeister S, Schepmann D, Wünsch B.. (2018) Pyridine bioisosteres of potent GluN2B subunit containing NMDA receptor antagonists with benzo[7]annulene scaffold., 157 [PMID:30103189] [10.1016/j.ejmech.2018.08.003] |
| 43. Unpublished dataset, |
| 44. David E Gordon, Gwendolyn M Jang, Mehdi Bouhaddou, Jiewei Xu, Kirsten Obernier, Kris M White, Matthew J O'Meara, Veronica V Rezelj, Jeffrey Z Guo, Danielle L Swaney, et al. (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, [PMID:32353859] [10.1038/s41586-020-2286-9] |
| 45. Burnell ES, Irvine M, Fang G, Sapkota K, Jane DE, Monaghan DT.. (2018) Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action., 62 (1): [PMID:29446949] [10.1021/acs.jmedchem.7b01640] |
| 46. Temme L, Börgel F, Schepmann D, Robaa D, Sippl W, Daniliuc C, Wünsch B.. (2019) Impact of hydroxy moieties at the benzo[7]annulene ring system of GluN2B ligands: Design, synthesis and biological evaluation., 27 (23): [PMID:31648876] [10.1016/j.bmc.2019.115146] |
| 47. Baumeister S, Schepmann D, Wünsch B.. (2019) Synthesis and receptor binding of thiophene bioisosteres of potent GluN2B ligands with a benzo[7]annulene-scaffold., 10 (2): [PMID:30881618] [10.1039/C8MD00545A] |
| 48. Baumeister S, Schepmann D, Wünsch B.. (2020) Thiophene bioisosteres of GluN2B selective NMDA receptor antagonists: Synthesis and pharmacological evaluation of [7]annuleno[b]thiophen-6-amines., 28 (2): [PMID:31843460] [10.1016/j.bmc.2019.115245] |
| 49. Zampieri D, Fortuna S, Calabretti A, Romano M, Menegazzi R, Schepmann D, Wünsch B, Mamolo MG.. (2020) Synthesis, Cytotoxicity Evaluation, and Computational Insights of Novel 1,4-Diazepane-Based Sigma Ligands., 11 (5): [PMID:32435366] [10.1021/acsmedchemlett.9b00524] |
| 50. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
| 51. Temme L,Bechthold E,Schreiber JA,Gawaskar S,Schepmann D,Robaa D,Sippl W,Seebohm G,Wünsch B. (2020) Negative allosteric modulators of the GluN2B NMDA receptor with phenylethylamine structure embedded in ring-expanded and ring-contracted scaffolds., 190 [PMID:32070917] [10.1016/j.ejmech.2020.112138] |
| 52. Yokoyama T, Kashihara M, Mizuguchi M.. (2021) Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors., 64 (19.0): [PMID:34547896] [10.1021/acs.jmedchem.1c00823] |
| 53. Turgutalp B, Bhattarai P, Ercetin T, Luise C, Reis R, Gurdal EE, Isaak A, Biriken D, Dinter E, Sipahi H, Schepmann D, Junker A, Wünsch B, Sippl W, Gulcan HO, Kizil C, Yarim M.. (2022) Discovery of Potent Cholinesterase Inhibition-Based Multi-Target-Directed Lead Compounds for Synaptoprotection in Alzheimer's Disease., 65 (18.0): [PMID:36084304] [10.1021/acs.jmedchem.2c01003] |
| 54. Xu Q, Hu M, Li J, Ma X, Chu Z, Zhu Q, Zhang Y, Zhu P, Huang Y, He G.. (2022) Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents., 227 [PMID:34710748] [10.1016/j.ejmech.2021.113876] |
| 55. Yang C, Wang H, Yang J, Zhang Y, Qin F, He Y, Liu J, Ma C, Cheng M.. (2023) Identification and in silicon binding study of a novel NR2B selective NMDAR antagonist., 85 [PMID:36870623] [10.1016/j.bmcl.2023.129213] |
| 56. Chen X, Zhu H, Liu X, Li Q, Dong M.. (2023) Design and synthesis of novel GluN2A NMDAR positive allosteric modulators via scaffold hopping strategy as anti-stroke therapeutic agents., 83 [PMID:36934527] [10.1016/j.bmc.2023.117236] |
| 57. Sutherland JJ, Yonchev D, Fekete A, Urban L.. (2023) A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs., 14 (1): [PMID:37468498] [10.1038/s41467-023-40064-9] |
